



LITERATURA

1. Alam A, Hana Z, Jin Z, Suen KC, Ma D. Surgery, neuroinflammation and cognitive impairment. *EBioMedicine* 2018; 37: 547–556.
2. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillsen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006; 355: 549–559.
3. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar A. The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. *Biofactors* 2019 Dec 17. doi: 10.1002/biof.1597.
4. Bednařík J, Vlčková E, Horák T. Statinová myopatie. *Neurol. praxi* 2017; 18(1): 15–19.
5. Ciurleo R, Bramanti P, Marino S. Role of statins in the treatment of multiple sclerosis. *Pharmacol Res* 2014; 87: 133–143.
6. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Low M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388: 2532–2561.
7. Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M. Statins and the Brain: More than Lipid Lowering Agents? *Curr Neuroparmacol* 2019; 17(1): 59–83.
8. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillsen H, Zivin JA, Welch KM; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. *Neurology* 2008; 70: 2364–2370.
9. Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. *Lancet* 2018; 392(10153): 1127–1137.
10. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. *Pharmacotherapy* 2010; 30: 541–553.
11. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CHRM, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet* 2014; 383(9936): 2213–2221.
12. Chen CJ, Ding D, Ironside N, Buell TJ, Elder LJ, Warren A, Adams AP, Ratcliffe SJ, James RF, Naval NS, Worrall BB, Johnston KC, Southerland AM. Statins for neuroprotection in spontaneous intracerebral hemorrhage. *Neurology* 2019; 93(24): 1056–1066.
13. Chen PS, Cheng CL, Chang YC, Kao Yang YH, Yeh PS, Li YH. Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. *Eur J Neurol* 2015; 22: 773–780.
14. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380: 581–590.
15. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019; 393: 407–415.
16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *Am J Cardiol* 2003; 92(2): 152–160.
17. Karki K, Knight RA, Han Y, et al. Simvastatin and atorvastatin improve neuro-logical outcome after experimental intracerebral hemorrhage. *Stroke* 2009; 40: 3384–3389.
18. Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzio M, Palladino R, Chataway J, Brescia Morra V. Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. *Mult Scler Relat Disord* 2019; 28: 193–196.
19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003; 326(7404): 1423.
20. Lei C, Wu B, Liu M, Chen Y. Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis. *Eur J Neurol* 2014; 21: 192–198.
21. Liao JK, Laufs U. Pleiotropic effects of statins. *Annu Rev Pharmacol Toxicol* 2005; 45: 89–118.
22. Lokhandwala A, Hanna K, Gries L, Zeeshan M, Ditillo M, Tang A, Hamidi M, Joseph B. Preinjury Statins Are Associated With Improved Survival in Patients With Traumatic Brain Injury. *J Surg Res* 2020; 245: 367–372.
23. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoğlu L, Vladutiu GD, Gencert B, Stock JK, Ginsberg HN, Chapman MJ, European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J* 2018; 39(27): 2526–2539.